The U.S. Food and Drug Administration (FDA) is set to conduct a comprehensive six-month safety review of mifepristone, a medication used for early pregnancy termination, following sustained pressure from anti-abortion lawmakers and activists. An administration official indicated that initial results might be available sooner than the full review timeline. The FDA has emphasized that it has been conducting this safety review for months, disputing claims that it was delaying the process. The review gained urgency following a leadership change at the FDA, with acting Commissioner Kyle Diamantis now overseeing the efforts. Diamantis has faced scrutiny due to his previous involvement with Planned Parenthood, but Trump allies have defended his appointment, stating he distanced himself from the case due to anti-abortion beliefs. Mifepristone was first approved by the FDA in 2000 and is typically used alongside misoprostol. Despite restrictions in conservative states, medication abortion remains accessible through mail-order pharmacies and state laws that protect clinicians from prosecution.